News

Metabolic health declining among the obese, despite improvements in BP and lipids


 

FROM THE JOURNAL OF THE AMERICAN HEART ASSOCIATION

References

The study was supported by the Department of Veterans Affairs, the National Institutes of Health, and the University of Alabama Diabetes Research Center.

Dr. Guo had no financial disclosures. Dr. Garvey disclosed relationships with multiple pharmaceutical companies.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

In T1D, quality of life measures fall short
Type 2 Diabetes ICYMI
What difference would an empagliflozin CVD indication make?
Type 2 Diabetes ICYMI
High rates of early complications seen in youth with diabetes
Type 2 Diabetes ICYMI
Statement warns of drugs causing or exacerbating heart failure
Type 2 Diabetes ICYMI
Canagliflozin benefits cohort of type 1 diabetes patients
Type 2 Diabetes ICYMI
Triple therapy helped type 1 patients improve glycemia
Type 2 Diabetes ICYMI
Newer insulin glargine formula curbs nocturnal hypoglycemia
Type 2 Diabetes ICYMI
Follow-up Findings From ACCORD
Type 2 Diabetes ICYMI
Newer Insulin Glargine Formula Curbs Nocturnal Hypoglycemia
Type 2 Diabetes ICYMI
Triple Therapy Helped Type 1 Patients Improve Glycemia
Type 2 Diabetes ICYMI